Literature DB >> 18443270

Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition.

Aneire E Khan1, Valentina Gallo, Jakob Linseisen, Rudolf Kaaks, Sabine Rohrmann, Ole Raaschou-Nielsen, Anne Tjønneland, Hans E Johnsen, Kim Overvad, Manuela M Bergmann, Heiner Boeing, Vasiliki Benetou, Theodora Psaltopoulou, Antonia Trichopoulou, Giovanna Masala, Amalia Mattiello, Sara Grioni, Rosario Tumino, Roel C H Vermeulen, Petra H M Peeters, H Bas Bueno-de-Mesquita, Martine M Ros, Eiliv Lund, Eva Ardanaz, María-Dolores Chirlaque, Paula Jakszyn, Nerea Larrañaga, Adamina Losada, Nikolaus Becker, Alexandra Nieters, Carmen Martínez-García, Asa Agren, Göran Hallmans, Göran Berglund, Jonas Manjer, Naomi E Allen, Timothy J Key, Sheila Bingham, Kay Tee Khaw, Nadia Slimani, Pietro Ferrari, Paolo Boffetta, Teresa Norat, Paolo Vineis, Elio Riboli.   

Abstract

BACKGROUND: Non-Hodgkin's lymphomas are a heterogeneous group of neoplasms arising from the lymphopoietic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few established risk factors for the development of these neoplasms include viral infections and immunological abnormalities, but their etiology remains largely unknown. Evidence suggests that certain medical conditions may be linked, through immunosuppression, to the risk of non-Hodgkin's lymphoma. Multiple myeloma is a neoplasm of plasma cells that accounts for approximately 15% of lymphopoietic cancers. Increases in the incidence of non-Hodgkin's lymphoma and multiple myeloma in the past implicate environmental factors as potential causal agents. DESIGN AND METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC), 1,213 histologically confirmed incident cases of non-Hodgkin's lymphoma and multiple myeloma (594 men; 619 women) were identified during a follow-up of 8.5 years. Cox proportional hazard models were used to explore the association between self-reported diabetes, diagnosed after 30 years of age, and the risk of non-Hodgkin's lymphoma overall and multiple myeloma and various lymphoma subtypes.
RESULTS: We found no association between a personal history of diabetes and the risk of non-Hodgkin's lymphoma overall in men (HR: 1.28, 95% CI: 0.89-1.84), in women (HR: 0.71, 95% CI: 0.41- 1.24), or in men and women combined (HR: 1.09, 95% CI: 0.80-1.47). Among the B-non-Hodgkin's lymphoma subtypes, we observed a statistically significant increased risk of B-cell chronic lymphocytic leukemia (HR: 2.0, 95% CI: 1.04-3.86) in men, but not in women (HR: 1.07, 95% CI: 0.33-3.43).
CONCLUSIONS: This prospective study did not provide evidence for a role of self-reported diabetes in the etiology of non-Hodgkin's lymphoma overall or multiple myeloma. We found an increased risk of B-cell chronic lymphocytic leukemia among men with diabetes, but not among women. We hypothesize that diabetes may not play a causal role in the etiology of B-cell chronic lymphocytic leukemia, though the underlying pathogenic mechanisms of both disorders may include shared genetic, host and/or environmental susceptibility factors.

Entities:  

Mesh:

Year:  2008        PMID: 18443270     DOI: 10.3324/haematol.12297

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.

Authors:  Emelie Curovic Rotbain; Carsten Utoft Niemann; Klaus Rostgaard; Caspar da Cunha-Bang; Henrik Hjalgrim; Henrik Frederiksen
Journal:  Leukemia       Date:  2021-02-18       Impact factor: 11.528

2.  Type 2 diabetes and the risk of non-Hodgkin's lymphoma: a report from two population-based cohort studies in China.

Authors:  Wan-Shui Yang; Hong-Lan Li; Hong-Li Xu; Gong Yang; Yu-Tang Gao; Wei Zheng; Xiao-Ou Shu; Yong-Bing Xiang
Journal:  Eur J Cancer Prev       Date:  2016-03       Impact factor: 2.497

3.  Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies.

Authors:  Jorge J Castillo; Nikhil Mull; John L Reagan; Saed Nemr; Joanna Mitri
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

4.  Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis.

Authors:  José Manuel Sánchez-Maldonado; Ricardo Collado; Antonio José Cabrera-Serrano; Rob Ter Horst; Fernando Gálvez-Montosa; Inmaculada Robles-Fernández; Verónica Arenas-Rodríguez; Blanca Cano-Gutiérrez; Olivier Bakker; María Inmaculada Bravo-Fernández; Francisco José García-Verdejo; José Antonio López López; Jesús Olivares-Ruiz; Miguel Ángel López-Nevot; Laura Fernández-Puerta; José Manuel Cózar-Olmo; Yang Li; Mihai G Netea; Manuel Jurado; Jose Antonio Lorente; Pedro Sánchez-Rovira; María Jesús Álvarez-Cubero; Juan Sainz
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

5.  Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis.

Authors:  M Chadeau-Hyam; R C H Vermeulen; D G A J Hebels; R Castagné; G Campanella; L Portengen; R S Kelly; I A Bergdahl; B Melin; G Hallmans; D Palli; V Krogh; R Tumino; C Sacerdote; S Panico; T M C M de Kok; M T Smith; J C S Kleinjans; P Vineis; S A Kyrtopoulos
Journal:  Ann Oncol       Date:  2014-02-20       Impact factor: 32.976

6.  Epidemiologic overview of malignant lymphoma.

Authors:  Jooryung Huh
Journal:  Korean J Hematol       Date:  2012-06-26

7.  Multiple myeloma and diabetes.

Authors:  Zeinab A Issa; Mira S Zantout; Sami T Azar
Journal:  ISRN Endocrinol       Date:  2011-11-17

Review 8.  Clinical challenges: myeloma and concomitant type 2 diabetes.

Authors:  Yasar Albushra Abdul Rahiem Ahmed; Awad Eltayeb
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

9.  Clinical challenges: Myeloma and concomitant type 2 diabetes.

Authors:  Mohamed Ahmed Ali; Yasar A Ahmed; Abubaker Ibrahim
Journal:  South Asian J Cancer       Date:  2013-10

10.  Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

Authors:  Silvia Bruno; Bernardetta Ledda; Claudya Tenca; Silvia Ravera; Anna Maria Orengo; Andrea Nicola Mazzarello; Elisa Pesenti; Salvatore Casciaro; Omar Racchi; Fabio Ghiotto; Cecilia Marini; Gianmario Sambuceti; Andrea DeCensi; Franco Fais
Journal:  Oncotarget       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.